Exelixis Inc at William Blair Biotech Focus Conference Transcript
Great. Thanks, everybody, for joining. Thanks for your participation in our Biotech Focus Conference this year. We're really pleased to have the management team of Exelixis, Mike Morrissey, CEO of the company; and Peter Lamb, CSO of the company, to discuss current progress and what's in store for the next 6 to 12 months for the company.
Before I begin, I need to let you know that for a full list of disclosures and conflicts, please visit our website.
So Mike, it's been a great year for Exelixis, right? CABOMETYX continues to launch well in first-line RCC, catalyst-rich second half, which we'll touch on the 3 Phase III trial readouts. Strong balance sheet, right, $2 billion in the bank. So maybe you could provide us with a quick snapshot of where the business is. And yes, we'll kind of dig deeper into the pipeline and catalysts.
Sounds good. Well, you gave a great
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
